Nature Communications (Jul 2019)
Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
Abstract
The efficacy of oncolytic adenoviruses is limited by strong immune responses being induced against the oncolytic virus itself. Here, the authors generate a bispecific molecule capable of redirecting the adenovirus-specific antibodies to tumour cells and show this induces immune mediated cancer growth inhibition and enhances the therapeutic efficacy of viral oncolysis.